These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1648 related items for PubMed ID: 24354905

  • 1. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2344-53. PubMed ID: 22463922
    [Abstract] [Full Text] [Related]

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L, Robinson JG.
    Prog Cardiovasc Dis; 2015 Jun 19; 58(1):19-31. PubMed ID: 25936907
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD.
    N Engl J Med; 2012 Mar 22; 366(12):1108-18. PubMed ID: 22435370
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I.
    Atheroscler Suppl; 2015 May 22; 18():21-7. PubMed ID: 25936300
    [Abstract] [Full Text] [Related]

  • 9. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 14. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA.
    JAMA; 2012 Dec 19; 308(23):2497-506. PubMed ID: 23128163
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
    Cicero AF, Tartagni E, Ertek S.
    Expert Opin Biol Ther; 2014 Jun 19; 14(6):863-8. PubMed ID: 24661068
    [Abstract] [Full Text] [Related]

  • 17. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H, Melone M, Rashid S.
    Expert Rev Cardiovasc Ther; 2014 Oct 19; 12(10):1137-44. PubMed ID: 25244623
    [Abstract] [Full Text] [Related]

  • 18. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, Luo H, Cai Y, Zeng C.
    J Am Heart Assoc; 2015 Jun 15; 4(6):e001937. PubMed ID: 26077586
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
    Stein EA, Swergold GD.
    Curr Atheroscler Rep; 2013 Mar 15; 15(3):310. PubMed ID: 23371064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.